ras mutation and expression of the ras‐regulated genes osteopontin and cathepsin L in human esophageal cancer

As part of our ongoing studies to characterize molecular alterations in a well‐defined series of surgically resected esophageal cancers, we examined the expression of 2 ras‐regulated genes, whose products (osteopontin and cathepsin L) previously were shown to be associated with tumor invasion and metastasis. RNA was extracted from primary esophageal tumors (adenocarcinomas, 19; squamous‐cell carcinomas, 6) and matched histologically normal esophageal mucosa from the distant resection margin. Northern analysis was used to quantitate RNA, relative to an 18S rRNA control, and immunohistochemistry to assess the tissue distribution of osteopontin. In addition, H‐, K‐ and N‐ras mutations were studied in the same tissues using PCR and hybridization with allele (mutant)‐specific oligonucleotide probes. We demonstrated a K‐ras mutation (codon 12, GTT) in one esophageal adenocarcinoma. The ras‐regulated gene osteopontin was over‐expressed in 100% of squamous‐cell carcinomas and in 58% of adenocarcinomas relative to matched normal esophageal mucosa. Patterns of immunoreactivity for osteopontin protein also varied between squamous‐cell carcinomas (tumor cell staining) and adenocarcinomas (predominantly tumor‐infiltrating macrophages). Expression of cathepsin L also varied with esophageal tumor histology, with over‐expression in 58% of primary esophageal adenocarcinomas and 33% of squamous‐cell cancers. Int. J. Cancer 72:739–745, 1997. © 1997 Wiley‐Liss, Inc.

[1]  J. F. Harris,et al.  Osteopontin expression in lung cancer. , 1996, Lung cancer.

[2]  Ruggero Montesano,et al.  Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review , 1996, International journal of cancer.

[3]  H. Yamasaki,et al.  High frequency of ki‐ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus , 1995, Molecular carcinogenesis.

[4]  F. O'Malley,et al.  Prognostic value of p53 protein in esophageal adenocarcinoma , 1995, Journal of surgical oncology.

[5]  S. Mousses,et al.  Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  A. Chambers,et al.  Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell , 1995, Molecular and cellular biology.

[7]  A. Chambers,et al.  Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. , 1994, The Journal of biological chemistry.

[8]  A. Craig,et al.  Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. , 1994, Cancer research.

[9]  H. Yamasaki,et al.  G→A mutations in p53 and Ha‐ras genes in esophageal papillomas induced by N‐nitrosomethylbenzylamine in two strains of rats , 1994, Molecular carcinogenesis.

[10]  A. Chambers,et al.  p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: a prospective study. , 1994, Cancer detection and prevention.

[11]  D. Denhardt,et al.  Osteopontin: a protein with diverse functions , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  S. Hirohashi,et al.  Possible role of activated ras genes in human esophageal carcinogenesis , 1993, International journal of cancer.

[13]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[14]  A. Chambers,et al.  Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. , 1992, Anticancer research.

[15]  A. Chambers,et al.  Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras‐transformed NIH 3T3 cells , 1992, Molecular carcinogenesis.

[16]  J. Roth,et al.  p53 gene mutations in Barrett's epithelium and esophageal cancer. , 1991, Cancer research.

[17]  R Montesano,et al.  Frequent mutation of the p53 gene in human esophageal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  O. Mcbride,et al.  cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). , 1990, Genomics.

[19]  D. Skinner,et al.  Expression of ras oncogene p21 protein in esophageal squamous cell carcinoma , 1990, Journal of surgical oncology.

[20]  Marshall W. Anderson,et al.  Mutational activation of the cellular Harvey ras oncogene in rat esophageal papillomas induced by methylbenzylnitrosamine. , 1990, Cancer research.

[21]  P. Waterhouse,et al.  Close relationship of the major excreted protein of transformed murine fibroblasts to thiol-dependent cathepsins. , 1986, Cancer research.